Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Dow Jones Futures - Jun 24

CME
Currency in USD
Disclaimer
38,324.00
+36.00(+0.09%)
Delayed Data

Dow Jones Futures Discussions

06.28 An institute of biological products in Beijing affiliated with the China National Pharmaceutical Group (Sinopharm) announced on Sunday that it had achieved positive results for a COVID-19 vaccine candidate it developed. Three of the four inactivated COVID-19 vaccines developed in China evoked positive immune responses in Phase I and II clinical trials, indicating that China has made great progress in the research and development (R&D) of this type of vaccine, experts said. The Beijing institute, which is under the Sinopharm China National Biotec Group (CNBG), said in a statement sent to the Global Times that all 1,120 volunteers in the first and second phase clinical trials successfully produced high-titer antibodies against COVID-19 after accepting two doses of the vaccine. The vaccine has proven to be effective and safe, read the statement!
You realize this is not a good news for the US, it has to be an american company otherwise it is not a cure
 https://finance.yahoo.com/news/chinese-firm-says-coronavirus-vaccine-080922778.html
This doesn’t mean “good news” necessarily anyways. Until there is a for sure guaranteed vaccine that works then nothing matters it’s the same stuff since January for all biotech companies
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.